Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

ACCESSWIRE

2024-11-01

WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.

Conference Call and Webcast Information

Event:	Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call
Date:	Thursday, November 14, 2024
Time:	10:00am ET
Conference Call:	1-877-877-1275 (U.S.) 1-412-858-5202 (international)
Webcast:	Webcast \| Third Quarter 2024 Financial Results and Business Update Conference Call

About Biofrontera Inc.

Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers¹. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.

1 - https://www.skincancer.org/skin-cancer-information/actinic-keratosis/

Contacts:

Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com

SOURCE: Biofrontera Inc.

View the original press release on accesswire.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2480839940"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480839940\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2480839940?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PFJRH16xceH_cOOcsPIYjw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/76b73e1af1285930cde94d0663b67002","is_english":true,"pubTime":"2024-11-01 23:55","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2480839940","market":"us","top_or_hot":-1,"title":"Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024","media":"ACCESSWIRE","content":"<html><body><p><strong>WOBURN, MA / ACCESSWIRE / November 1, 2024 / <a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a>. (Nasdaq:BFRI) (\"Biofrontera\" or the \"Company\")</strong>, a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.</p>\n<p><strong>Conference Call and Webcast Information</strong></p>\n<figure>\n<table>\n<tbody>\n<tr>\n<td><p><span><strong>Event:</strong></span></p></td>\n<td><p><span><strong>Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Date:</strong></span></p></td>\n<td><p><span><strong>Thursday, November 14, 2024</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Time:</strong></span></p></td>\n<td><p><span><strong>10:00am ET</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Conference Call:</strong></span></p></td>\n<td><p><span><strong>1-877-877-1275 (U.S.)</strong></span></p><p><span><strong>1-412-858-5202 (international)</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Webcast:</strong></span></p></td>\n<td><p><span><strong>Webcast | Third Quarter 2024 Financial Results and Business Update Conference Call</strong></span></p></td>\n</tr>\n</tbody>\n</table>\n</figure>\n<p><strong>About Biofrontera Inc.</strong></p>\n<p>Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers<sup>1</sup>. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.</p>\n<p><strong>1 - </strong><strong>https://www.skincancer.org/skin-cancer-information/actinic-keratosis/</strong></p>\n<p><strong>Contacts:</strong></p>\n<p>Investor Relations<br/>Andrew Barwicki<br/>1-516-662-9461<br/>ir@bfri.com<br/><br/><br/></p>\n<p><strong>SOURCE: </strong>Biofrontera Inc.</p>\n<br/>\n<br/>View the original \npress release on accesswire.com\n<br/>\n<br/>\n<br/>\n<br/>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">ACCESSWIRE</strong><span class=\"h-time small\">2024-11-01 23:55</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p><strong>WOBURN, MA / ACCESSWIRE / November 1, 2024 / <a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a>. (Nasdaq:BFRI) (\"Biofrontera\" or the \"Company\")</strong>, a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.</p>\n<p><strong>Conference Call and Webcast Information</strong></p>\n<figure>\n<table>\n<tbody>\n<tr>\n<td><p><span><strong>Event:</strong></span></p></td>\n<td><p><span><strong>Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Date:</strong></span></p></td>\n<td><p><span><strong>Thursday, November 14, 2024</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Time:</strong></span></p></td>\n<td><p><span><strong>10:00am ET</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Conference Call:</strong></span></p></td>\n<td><p><span><strong>1-877-877-1275 (U.S.)</strong></span></p><p><span><strong>1-412-858-5202 (international)</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Webcast:</strong></span></p></td>\n<td><p><span><strong>Webcast | Third Quarter 2024 Financial Results and Business Update Conference Call</strong></span></p></td>\n</tr>\n</tbody>\n</table>\n</figure>\n<p><strong>About Biofrontera Inc.</strong></p>\n<p>Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers<sup>1</sup>. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.</p>\n<p><strong>1 - </strong><strong>https://www.skincancer.org/skin-cancer-information/actinic-keratosis/</strong></p>\n<p><strong>Contacts:</strong></p>\n<p>Investor Relations<br/>Andrew Barwicki<br/>1-516-662-9461<br/>ir@bfri.com<br/><br/><br/></p>\n<p><strong>SOURCE: </strong>Biofrontera Inc.</p>\n<br/>\n<br/>View the original \npress release on accesswire.com\n<br/>\n<br/>\n<br/>\n<br/>\n<br/></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/biofrontera-inc-report-third-quarter-155500583.html\">ACCESSWIRE</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BFRI","symbol_name":"Biofrontera Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/biofrontera-inc-report-third-quarter-155500583.html","article_id":"2480839940","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PFJRH16xceH_cOOcsPIYjw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/76b73e1af1285930cde94d0663b67002"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480839940","pubTimestamp":1730476500,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc.  , a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. Webcast | Third Quarter 2024 Financial Results and Business Update Conference Call. Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to exte","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BFRI":"Biofrontera Inc","BK4007":"制药","BFRIW":"Biofrontera Inc Warrant"},"translate_title":"Biofrontera Inc.将于2024年11月13日报告第三季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BFRI":1,"BFRIW":0.9},"content_text":"WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) (\"Biofrontera\" or the \"Company\"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.\nConference Call and Webcast Information\n\n\n\n\nEvent:\nBiofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call\n\n\nDate:\nThursday, November 14, 2024\n\n\nTime:\n10:00am ET\n\n\nConference Call:\n1-877-877-1275 (U.S.)1-412-858-5202 (international)\n\n\nWebcast:\nWebcast | Third Quarter 2024 Financial Results and Business Update Conference Call\n\n\n\n\nAbout Biofrontera Inc.\nBiofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.\n1 - https://www.skincancer.org/skin-cancer-information/actinic-keratosis/\nContacts:\nInvestor RelationsAndrew Barwicki1-516-662-9461ir@bfri.com\nSOURCE: Biofrontera Inc.\n\nView the original \npress release on accesswire.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}